Mechanisms of checkpoint inhibition-induced adverse events.
CTLA-4
PD-1
cancer
checkpoint
immunotherapy
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
12
12
2019
pubmed:
29
1
2020
medline:
21
10
2020
entrez:
29
1
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCLC). Drugs targeting cytotoxic T lymphocyte antigen (CTLA)-4 and programmed cell death 1 (PD-1) have made their way into routine clinical use; however, this has not been without difficulties. Stimulation of the immune system to target cancer has been found to result in a reduction of self-tolerance, leading to the development of adverse effects that resemble autoimmunity. These adverse effects are erratic in their onset and severity and can theoretically affect any organ type. Several mechanisms for immune-related toxicity have been investigated over recent years; however, no consensus on the cause or prediction of toxicity has been reached. This review seeks to examine reported evidence for possible mechanisms of toxicity, methods for prediction of those at risk and a discussion of future prospects within the field.
Identifiants
pubmed: 31989585
doi: 10.1111/cei.13421
pmc: PMC7160658
doi:
Substances chimiques
Antineoplastic Agents
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Neoplasm Proteins
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-154Subventions
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Informations de copyright
© 2020 British Society for Immunology.
Références
Cancer Res. 2017 Mar 15;77(6):1322-1330
pubmed: 28031229
J Clin Oncol. 2015 Jun 20;33(18):2004-12
pubmed: 25897158
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Eur J Cancer. 2019 Jan;107:142-152
pubmed: 30576970
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
Curr Opin Oncol. 2016 Jul;28(4):306-13
pubmed: 27136134
Clin Exp Immunol. 2016 Aug;185(2):252-62
pubmed: 27010233
J Immunother Cancer. 2015 Sep 15;3:39
pubmed: 26380086
Nat Immunol. 2009 Jan;10(1):29-37
pubmed: 19043418
J Immunother. 2006 Jul-Aug;29(4):455-63
pubmed: 16799341
JAMA Oncol. 2019 Jul 1;5(7):1049-1054
pubmed: 30730549
Br J Cancer. 2017 Jan;116(3):310-317
pubmed: 28072766
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Clin Oncol. 2006 May 20;24(15):2283-9
pubmed: 16710025
J Clin Oncol. 2015 Oct 1;33(28):3193-8
pubmed: 26282644
JAMA Dermatol. 2015 Nov;151(11):1206-1212
pubmed: 26222619
Cancer. 2017 Jun 1;123(S11):2143-2153
pubmed: 28543699
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Immunology. 2000 Oct;101(2):169-77
pubmed: 11012769
Ann Oncol. 2018 Aug 1;29(8):1727-1740
pubmed: 29945232
Clin Cancer Res. 2014 May 1;20(9):2424-32
pubmed: 24583799
J Immunother. 2005 Nov-Dec;28(6):593-8
pubmed: 16224277
Cell. 2018 Nov 1;175(4):1014-1030.e19
pubmed: 30343900
Am J Pathol. 2016 Dec;186(12):3225-3235
pubmed: 27750046
Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):157-161
pubmed: 29255057
J Transl Med. 2013 Mar 22;11:75
pubmed: 23521917
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Clin Diagn Lab Immunol. 2005 Jun;12(6):705-12
pubmed: 15939744
J Clin Oncol. 2017 Mar;35(7):785-792
pubmed: 28068177
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
J Transl Med. 2018 Apr 11;16(1):94
pubmed: 29642948
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266
pubmed: 29917046
Ann Oncol. 2017 Jun 1;28(6):1368-1379
pubmed: 28368458
J Clin Oncol. 2005 Sep 1;23(25):6043-53
pubmed: 16087944
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
J Am Geriatr Soc. 2019 May;67(5):905-912
pubmed: 30698276
Nat Commun. 2016 Feb 02;7:10391
pubmed: 26837003
Front Oncol. 2018 Aug 23;8:315
pubmed: 30191140
J Transl Med. 2013 Apr 04;11:89
pubmed: 23557194
Clin Lung Cancer. 2019 Jul;20(4):237-247.e1
pubmed: 30885550
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Nat Med. 2018 Dec;24(12):1804-1808
pubmed: 30420754
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
J Clin Oncol. 2017 Dec 1;35(34):3807-3814
pubmed: 28841387
J Immunol. 1996 Dec 1;157(11):4762-70
pubmed: 8943377
Int J Cancer. 2019 Aug 1;145(3):639-648
pubmed: 30653255
J Immunother Cancer. 2019 Apr 16;7(1):106
pubmed: 30992053
J Transl Med. 2012 Jul 12;10:146
pubmed: 22788688
Ann Rheum Dis. 2017 Oct;76(10):1747-1750
pubmed: 28600350
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Annu Rev Immunol. 2016 May 20;34:539-73
pubmed: 26927206
Ann Oncol. 2017 Mar 1;28(3):583-589
pubmed: 27998967
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Hum Vaccin Immunother. 2018;14(9):2178-2182
pubmed: 29494275
Br J Cancer. 2018 Jul;119(2):153-159
pubmed: 29955135
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
Front Immunol. 2018 Mar 02;9:411
pubmed: 29552014
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11070-5
pubmed: 16033867
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Lancet Oncol. 2019 Jan;20(1):e54-e64
pubmed: 30614479
Br J Cancer. 2019 Jan;120(1):63-68
pubmed: 30377338
J Immunother. 2019 Apr;42(3):89-93
pubmed: 30768543
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Nature. 1987 Jul 16-22;328(6127):267-70
pubmed: 3496540
J Clin Oncol. 2015 Mar 1;33(7):773-81
pubmed: 25605840
PLoS One. 2018 Apr 23;13(4):e0195945
pubmed: 29684049
J Hematol Oncol. 2019 Jun 10;12(1):58
pubmed: 31182108
JAMA Oncol. 2016 Apr;2(4):463-9
pubmed: 26746479
J Clin Invest. 2018 Feb 1;128(2):715-720
pubmed: 29309048
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Clin Oncol. 2012 Jul 20;30(21):2691-7
pubmed: 22614989
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
J Transl Med. 2018 Apr 2;16(1):82
pubmed: 29606147
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924
pubmed: 27698113
J Clin Oncol. 2017 Mar;35(7):709-717
pubmed: 27646942
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563
pubmed: 30409824
Arch Dermatol. 2006 Feb;142(2):166-72
pubmed: 16490844
Cancer Cell. 2015 Apr 13;27(4):439-49
pubmed: 25858803
Immunity. 1996 Jun;4(6):535-43
pubmed: 8673700
Ann Oncol. 2017 Oct 1;28(10):2377-2385
pubmed: 28945858
Trends Immunol. 2015 Feb;36(2):63-70
pubmed: 25582039
Science. 2011 Apr 29;332(6029):600-3
pubmed: 21474713
J Exp Med. 2000 Jul 17;192(2):303-10
pubmed: 10899917
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936